by Peace Chukwu | Sep 5, 2024
From extracting insulin from the pancreas of cows to extreme diets and herbal remedies for glucose regulation, diabetes treatments over the century have evolved progressively, with each discovery extending the life span of patients a little longer than the last....
by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Lyla El-Fayomi | Jun 18, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Throughout the past month, I’ve spotted some notable trends emerging in the...
by Lyla El-Fayomi | May 23, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. I’ve gone slightly longer form with this month’s edition, as I found that...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
Comments